Traders sold shares of Gilead Sciences Inc. (NASDAQ:GILD) on strength during trading hours on Monday. $234.22 million flowed into the stock on the tick-up and $281.47 million flowed out of the stock on the tick-down, for a money net flow of $47.25 million out of the stock. Of all stocks tracked, Gilead Sciences had the 0th highest net out-flow for the day. Gilead Sciences traded up $2.00 for the day and closed at $88.55

Several equities analysts recently commented on GILD shares. Cowen and Company reissued a “buy” rating on shares of Gilead Sciences in a research report on Sunday, April 17th. Mizuho reissued a “buy” rating and set a $130.00 price target on shares of Gilead Sciences in a research report on Sunday, April 10th. Citigroup Inc. reissued a “buy” rating and set a $110.00 price target on shares of Gilead Sciences in a research report on Monday, March 28th. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $104.96 price target on the stock. in a research report on Monday, April 4th. Finally, Royal Bank Of Canada reissued a “buy” rating on shares of Gilead Sciences in a research report on Saturday, April 30th. Seven investment analysts have rated the stock with a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $114.05.

The firm has a market cap of $117.93 billion and a PE ratio of 7.56. The firm’s 50-day moving average is $84.73 and its 200-day moving average is $88.80.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.02 by $0.06. The business earned $7.78 billion during the quarter, compared to the consensus estimate of $7.80 billion. During the same period in the previous year, the business posted $3.15 EPS. Gilead Sciences’s revenue was down 5.7% compared to the same quarter last year. On average, equities research analysts predict that Gilead Sciences Inc. will post $12.02 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 29th. Investors of record on Friday, September 16th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 2.12%.

In related news, Chairman John C. Martin sold 100,000 shares of the firm’s stock in a transaction dated Monday, May 2nd. The shares were sold at an average price of $87.82, for a total value of $8,782,000.00. Following the transaction, the chairman now owns 4,119,727 shares of the company’s stock, valued at approximately $361,794,425.14. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO John F. Milligan sold 112,000 shares of the firm’s stock in a transaction dated Monday, May 2nd. The shares were sold at an average price of $87.71, for a total transaction of $9,823,520.00. Following the completion of the transaction, the chief executive officer now directly owns 1,170,963 shares in the company, valued at approximately $102,705,164.73. The disclosure for this sale can be found here.

Other institutional investors have made changes to their positions in the company. Sfmg LLC boosted its position in shares of Gilead Sciences by 5.2% in the fourth quarter. Sfmg LLC now owns 10,619 shares of the biopharmaceutical company’s stock valued at $1,075,000 after buying an additional 522 shares during the last quarter. Baxter Bros Inc. raised its stake in Gilead Sciences by 42.1% in the fourth quarter. Baxter Bros Inc. now owns 11,798 shares of the biopharmaceutical company’s stock valued at $1,194,000 after buying an additional 3,493 shares during the period. West Chester Capital Advisors Inc. raised its stake in Gilead Sciences by 2.9% in the fourth quarter. West Chester Capital Advisors Inc. now owns 11,912 shares of the biopharmaceutical company’s stock valued at $1,197,000 after buying an additional 339 shares during the period. P.A.W. Capital Corp raised its stake in Gilead Sciences by 9.1% in the fourth quarter. P.A.W. Capital Corp now owns 12,000 shares of the biopharmaceutical company’s stock valued at $1,214,000 after buying an additional 1,000 shares during the period. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC raised its stake in Gilead Sciences by 3.7% in the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 12,086 shares of the biopharmaceutical company’s stock valued at $1,223,000 after buying an additional 435 shares during the period.

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.